Comparative Pharmacology
Head-to-head clinical analysis: ENOXAPARIN versus LOVENOX PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOXAPARIN versus LOVENOX PRESERVATIVE FREE.
Enoxaparin vs LOVENOX (PRESERVATIVE FREE)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.
Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.
1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours after a single subcutaneous dose, and 7 hours after repeated dosing, reflecting accumulation. Mean half-life is approximately 4-5 hours in healthy volunteers.
Terminal half-life: 3-5 hours after subcutaneous injection; prolonged in renal impairment (up to 8-10 hours with CrCl <30 mL/min).
Renal elimination accounts for 40% of the administered dose, with the remainder undergoing hepatic metabolism and/or distribution. Biliary/fecal excretion is minimal (<5%).
Renal: 40-60% as unchanged drug and low molecular weight fragments via glomerular filtration; biliary/fecal: negligible.
Category A/B
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin